Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease - PubMed (original) (raw)

doi: 10.1038/nn1630. Epub 2006 Jan 15.

Qiu-Lan Ma, Frédéric Calon, Marni E Harris-White, Fusheng Yang, Giselle P Lim, Takashi Morihara, Oliver J Ubeda, Surendra Ambegaokar, James E Hansen, Richard H Weisbart, Bruce Teter, Sally A Frautschy, Greg M Cole

Affiliations

Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease

Lixia Zhao et al. Nat Neurosci. 2006 Feb.

Abstract

Defects in dendritic spines are common to several forms of cognitive deficits, including mental retardation and Alzheimer disease. Because mutation of p21-activated kinase (PAK) can lead to mental retardation and because PAK-cofilin signaling is critical in dendritic spine morphogenesis and actin dynamics, we hypothesized that the PAK pathway is involved in synaptic and cognitive deficits in Alzheimer disease. Here, we show that PAK and its activity are markedly reduced in Alzheimer disease and that this is accompanied by reduced and redistributed phosphoPAK, prominent cofilin pathology and downstream loss of the spine actin-regulatory protein drebrin, which cofilin removes from actin. We found that beta-amyloid (Abeta) was directly involved in PAK signaling deficits and drebrin loss in Abeta oligomer-treated hippocampal neurons and in the Appswe transgenic mouse model bearing a double mutation leading to higher Abeta production. In addition, pharmacological PAK inhibition in adult mice was sufficient to cause similar cofilin pathology, drebrin loss and memory impairment, consistent with a potential causal role of PAK defects in cognitive deficits in Alzheimer disease.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources